{"id":103891,"date":"2026-05-16T00:03:06","date_gmt":"2026-05-16T00:03:06","guid":{"rendered":"https:\/\/www.europesays.com\/afrique\/103891\/"},"modified":"2026-05-16T00:03:06","modified_gmt":"2026-05-16T00:03:06","slug":"sandoz-enrichit-son-offre-dinsuline-en-europe-avec-deux-produits","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/afrique\/103891\/","title":{"rendered":"Sandoz enrichit son offre d&rsquo;insuline en Europe avec deux produits"},"content":{"rendered":"<p style=\"margin-top:5px\">Zurich (awp) &#8211; Le g\u00e9ant des m\u00e9dicaments g\u00e9n\u00e9riques et biosimilaires Sandoz \u00e9toffe son offre d&rsquo;insuline en Europe. Son partenaire chinois Gan &amp; Lee Pharmaceuticals indique vendredi avoir obtenu le feu vert de la Commission europ\u00e9enne pour les succ\u00e9dan\u00e9s Bysumlog et Dazparda des pr\u00e9parations originales respectives Homalog (insuline lispro) et NovoRapid (insuline aspart).<\/p>\n<p>Propri\u00e9t\u00e9 d&rsquo;Eli Lilly, Homalog a rapport\u00e9 au mastodonte am\u00e9ricain plus de 2,3 milliards de dollars au niveau mondial en 2024. Son homologue danois a de son c\u00f4t\u00e9 engrang\u00e9 plus de 2,5 milliards de dollars avec son NovoRapid en 2025, souligne Gan &amp; Lee dans un communiqu\u00e9.<\/p>\n<p>Sandoz a rappel\u00e9 avoir paraph\u00e9 en 2018 un accord de distribution avec Gan &amp; Lee portant sur les versions biosimilaires d&rsquo;insulines aspart, lispro et glargine, portant notamment sur le Vieux continent.<\/p>\n<p>Homologu\u00e9e en janvier dernier par la Commission europ\u00e9enne, l&rsquo;insuline glargine de Gan &amp; Lee sera commercialis\u00e9s par Sandoz sous la marque Ondibta. La pr\u00e9paration originale Lantus avait g\u00e9n\u00e9r\u00e9 pour son propri\u00e9taire hexagonal Sanofi des revenus mondiaux de pr\u00e8s de 2,9 milliards d&rsquo;euros en 2024, dont 819 millions sur le seul march\u00e9 europ\u00e9en.<\/p>\n<p>jh\/al<\/p>\n","protected":false},"excerpt":{"rendered":"Zurich (awp) &#8211; Le g\u00e9ant des m\u00e9dicaments g\u00e9n\u00e9riques et biosimilaires Sandoz \u00e9toffe son offre d&rsquo;insuline en Europe. Son&hellip;\n","protected":false},"author":2,"featured_media":103892,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[207,18],"class_list":{"0":"post-103891","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-europe","8":"tag-bourse","9":"tag-europe"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@afrique\/116581328726818498","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/afrique\/wp-json\/wp\/v2\/posts\/103891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/afrique\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/afrique\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/afrique\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/afrique\/wp-json\/wp\/v2\/comments?post=103891"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/afrique\/wp-json\/wp\/v2\/posts\/103891\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/afrique\/wp-json\/wp\/v2\/media\/103892"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/afrique\/wp-json\/wp\/v2\/media?parent=103891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/afrique\/wp-json\/wp\/v2\/categories?post=103891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/afrique\/wp-json\/wp\/v2\/tags?post=103891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}